Drug Profile


Alternative Names: A-802710; BL 194; CT-1501R; ProTec

Latest Information Update: 10 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cell Therapeutics
  • Developer DiaKine Therapeutics; National Institute of Allergy and Infectious Diseases; National Institute of Diabetes and Digestive and Kidney Diseases
  • Class Adjuvants; Chemoprotectants; Nonsteroidal anti-inflammatories; Radiation-sensitising agents; Small molecules; Xanthines
  • Mechanism of Action Immunosuppressants; Interleukin 12 inhibitors; Lysophosphatidic acid acyltransferase inhibitors; STAT4 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Transplant rejection
  • Discontinued Acute lung injury; Chemotherapy-induced damage; Graft-versus-host disease; Mucositis; Neutropenia; Septic shock; Type 1 diabetes mellitus

Most Recent Events

  • 01 Sep 2014 The NIH completes a phase II trial in islet cell transplantation (Adjunctive treatment) in the US (NCT00464555)
  • 30 May 2014 Cell Therapeutics is now called CTI BioPharma
  • 01 May 2014 The NIH completes a phase III trial in islet cell transplantation (Adjunctive treatment) in the US (NCT00434811)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top